Chemiluminescence Immunoassay (CLIA) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Chemiluminescence Immunoassay (CLIA) Market is Segmented by Products Type (Analyzers, Reagents, and Consumables), Application, End-User, and Geography

Chemiluminescence Immunoassay (CLIA) Market Snapshot

Chemiluminescence Immunoassay (CLIA) Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Chemiluminescence Immunoassay (CLIA) market is anticipated to grow with a CAGR of 6.6% during the forecast period. The major factors attributing to the growth of the chemiluminescence immunoassay (CLIA) market are the rising incidence of chronic diseases such as cardiovascular diseases, diabetes, autoimmune diseases, cancer, and others.

The rise in the population suffering from chronic diseases is propelling the market growth. Heart disease continues to remain the major cause of death in the United States. In 2018, as per the AHA statistics, around 720,000 Americans have experienced a coronary event and around 335,000 have experienced a recurrent event. And there are few more factors which are playing key roles in taking the chemiluminescence immunoassay (CLIA) market to the next level, among them one is on-going developments related to chemiluminescence analyzers and its technology which are expected to further drive the growth of global chemiluminescence immunoassay (CLIA) market.

Scope of the Report

As per the scope of the report, chemiluminescence (CL) is described as the discharge of electromagnetic radiation owing to the production of light by a chemical reaction. Chemiluminescence immunoassay (CLIA) is an assay incorporating the technique of chemiluminescence with immunochemical reactions.

By Product Type
Analyzers
Automated
Semi-Automated
Reagents
Luminophore Markers
Enzymatic Markers
Consumables
By Application
Oncology
Autoimmune Disorder
Infectious Disease
Cardiovascular Disease
Endocrine Disorders
Others
By End User
Pharmaceutical and Biotechnology Companies
Hospital and Clinical Laboratories
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Reagents Segment is Expected to Hold the Largest Market Share in the Chemiluminescence Immunoassay (CLIA) Market

The reagents segment is expected to continue its dominance during the forecast period, owing to the relatively higher frequency of reagent replacement when compared to analyzer systems.

As per the statistics from GLOBOCAN 2018, worldwide 18,078,957 individuals have cancer. Asia remains the leading contributor in the rising incidence of cancer with a reported share of 48.4% followed by Europe, North and Latin America, Africa, and Oceania with a share of 23.4%, 13.2%, and 7.8%, 5.8%, and 1.4% respectively.

Therefore there is an increasing demand for ultra-sensitive disease diagnosis, better accuracy, and quality, and rising development in new testing options that are expected to drive the reagents market. Increasing demand for high-content diagnosis and clinical research for cancer, cardiovascular, and other chronic diseases, in particular, is also strengthening the market growth of reagents.

Chemiluminescence Immunoassay (CLIA) Market

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall chemiluminescence immunoassay (CLIA) market, throughout the forecast period. This is owing to factors such as the rising incidence of chronic diseases such as cardiovascular diseases and cancer and the revolution in test offerings is among the major factors. 

In the North America region, the United States holds the largest market share owing to factors such as the increasing number of populations suffering from cardiovascular diseases and other chronic diseases. As per the CDC (Centers for Disease Control and Prevention) and AHA, coronary heart disease is the main cause of deaths in the US accompanied by stroke, high blood pressure, coronary disease, heart failure, and other CVD. However, the rising geriatric population and developments related to chemiluminescence immunoassay (CLIA) in the country, will also contribute to stimulating the demand of CLIA in the region.

Chemiluminescence Immunoassay (CLIA) Market

Competitive Landscape

The chemiluminescence immunoassay (CLIA) market is moderately competitive and consists of major players. In terms of market share, few of the major players are currently dominating the market.  Some prominent players are vigorously making acquisitions and new product launches with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are F. Hoffmann-La Roche AG, Mindray Medical International Limited, Siemens Healthcare GmbH, Beckman Coulter Inc. (Danaher Corporation), and DiaSorin S.p.A.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Incidence of Chronic Diseases

      2. 4.2.2 Increasing Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Scarcity of Skilled Labor and Healthcare Professionals

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Analyzers

        1. 5.1.1.1 Automated

        2. 5.1.1.2 Semi-Automated

      2. 5.1.2 Reagents

        1. 5.1.2.1 Luminophore Markers

        2. 5.1.2.2 Enzymatic Markers

      3. 5.1.3 Consumables

    2. 5.2 By Application

      1. 5.2.1 Oncology

      2. 5.2.2 Autoimmune Disorder

      3. 5.2.3 Infectious Disease

      4. 5.2.4 Cardiovascular Disease

      5. 5.2.5 Endocrine Disorders

      6. 5.2.6 Others

    3. 5.3 By End User

      1. 5.3.1 Pharmaceutical and Biotechnology Companies

      2. 5.3.2 Hospital and Clinical Laboratories

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 F. Hoffmann-La Roche AG

      2. 6.1.2 Mindray Medical International Limited

      3. 6.1.3 Siemens Healthcare GmbH

      4. 6.1.4 Beckman Coulter Inc. (Danaher Corporation)

      5. 6.1.5 DiaSorin S.p.A.

      6. 6.1.6 Sysmex Corporation

      7. 6.1.7 Randox Laboratories Ltd.

      8. 6.1.8 Tosoh Corporation

      9. 6.1.9 Shenzhen New Industries Biomedical Engineering Co., Ltd.

      10. 6.1.10 BioMerieux

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Chemiluminescence Immunoassay (CLIA) Market market is studied from 2018 - 2026.

The Chemiluminescence Immunoassay (CLIA) Market is growing at a CAGR of 6.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

F. Hoffmann-La Roche AG, Mindray Medical International Limited, Siemens Healthcare GmbH, Beckman Coulter Inc. (Danaher Corporation), DiaSorin S.p.A. are the major companies operating in Chemiluminescence Immunoassay (CLIA) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!